Sophiris Bio (SPHS) Stock Price Down 7.9%

Shares of Sophiris Bio Inc (NASDAQ:SPHS) were down 7.9% during trading on Monday . The company traded as low as $1.90 and last traded at $1.97. Approximately 623,491 shares changed hands during mid-day trading, an increase of 141% from the average daily volume of 258,958 shares. The stock had previously closed at $2.14.

A number of analysts have commented on SPHS shares. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Sophiris Bio in a report on Friday, November 10th. ValuEngine raised Sophiris Bio from a “strong sell” rating to a “sell” rating in a report on Friday, December 15th. Finally, Maxim Group set a $6.00 price objective on Sophiris Bio and gave the stock a “buy” rating in a report on Monday, December 11th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $6.25.

The company has a debt-to-equity ratio of 0.60, a current ratio of 13.37 and a quick ratio of 13.37. The firm has a market cap of $64.44, a price-to-earnings ratio of -15.15 and a beta of 1.88.

Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). research analysts anticipate that Sophiris Bio Inc will post -0.26 EPS for the current year.

A hedge fund recently bought a new stake in Sophiris Bio stock. Mesirow Financial Investment Management Inc. acquired a new position in Sophiris Bio Inc (NASDAQ:SPHS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned 0.18% of Sophiris Bio at the end of the most recent reporting period. Institutional investors and hedge funds own 5.51% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Sophiris Bio (SPHS) Stock Price Down 7.9%” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.thestockobserver.com/2018/02/05/sophiris-bio-sphs-stock-price-down-7-9.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply